What is the initial adult dosage of Lidocaine for pulseless V Tach or V fib?

What is the initial adult dosage of Lidocaine for pulseless V Tach or V fib?

• A. 0.5 - 1 mg/kg
• B. 1 - 1.5 mg/kg
• C. 1.5 - 2 mg/kg
• D. 2 - 2.5 mg/kg

Answer: (B)

The initial adult dosage of Lidocaine for pulseless ventricular tachycardia (V Tach) or ventricular fibrillation (V Fib) is indeed 1 to 1.5 mg/kg. This dosing guideline is based on the pharmacological action of Lidocaine as an antiarrhythmic agent used to stabilize cardiac rhythms in emergency situations. Lidocaine functions primarily by blocking sodium channels in the cardiac tissue, which helps to restore normal electrical conduction and can terminate arrhythmias like V Tach and V Fib. The recommended dosage range ensures that the drug reaches therapeutic levels quickly to exert its effects, especially in life-threatening situations where immediate intervention is crucial. Administering less than this dosage could result in inadequate therapeutic effect, increasing the risk of persistent arrhythmias or cardiac arrest, while exceeding this dosage without appropriate medical oversight can lead to toxicity and serious side effects. The established range of 1 to 1.5 mg/kg has been derived from clinical studies and is widely accepted in Advanced Cardiac Life Support (ACLS) protocols, ensuring effective and safe administration of Lidocaine in critical care scenarios.

The initial adult dosage of Lidocaine for pulseless ventricular tachycardia (V Tach) or ventricular fibrillation (V Fib) is indeed 1 to 1.5 mg/kg. This dosing guideline is based on the pharmacological action of Lidocaine as an antiarrhythmic agent used to stabilize cardiac rhythms in emergency situations.

Lidocaine functions primarily by blocking sodium channels in the cardiac tissue, which helps to restore normal electrical conduction and can terminate arrhythmias like V Tach and V Fib. The recommended dosage range ensures that the drug reaches therapeutic levels quickly to exert its effects, especially in life-threatening situations where immediate intervention is crucial.

Administering less than this dosage could result in inadequate therapeutic effect, increasing the risk of persistent arrhythmias or cardiac arrest, while exceeding this dosage without appropriate medical oversight can lead to toxicity and serious side effects. The established range of 1 to 1.5 mg/kg has been derived from clinical studies and is widely accepted in Advanced Cardiac Life Support (ACLS) protocols, ensuring effective and safe administration of Lidocaine in critical care scenarios.